Entera Bio Ltd
Company Profile
Business description
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Contact
Minrav Building - Fifth Floor
Kiryat Hadassah
Jerusalem9112002
ISRT: +972 25327151
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
21
Stocks News & Analysis
stocks
Picking dividend shares in 2026? Here’s where to look
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,832.60 | 24.00 | -0.27% |
| CAC 40 | 8,119.02 | 51.07 | -0.63% |
| DAX 40 | 23,590.52 | 286.03 | -1.20% |
| Dow JONES (US) | 46,590.24 | 557.24 | -1.18% |
| FTSE 100 | 9,675.43 | 22.94 | -0.24% |
| HKSE | 26,384.28 | 188.18 | -0.71% |
| NASDAQ | 22,708.07 | 192.52 | -0.84% |
| Nikkei 225 | 49,667.67 | 656.24 | -1.30% |
| NZX 50 Index | 13,453.10 | 45.94 | -0.34% |
| S&P 500 | 6,672.41 | 61.70 | -0.92% |
| S&P/ASX 200 | 8,558.20 | 20.60 | -0.24% |
| SSE Composite Index | 3,972.03 | 18.46 | -0.46% |